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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is currently the fifth leading cause of death worldwide.
Neutrophilic inflammation is prominent, worsened during infective exacerbations and is refractory to glucocorticosteroids
(GCs). Deregulated neutrophilic inflammation can cause excessive matrix degradation through proteinase release.
Gelatinase and azurophilic granules within neutrophils are a major source of matrix metalloproteinase (MMP)-9 and
neutrophil elastase (NE), respectively, which are elevated in COPD.
Methods: Secreted MMP-9 and NE activity in BALF were stratified according to GOLD severity stages. The regulation of
secreted NE and MMP-9 in isolated blood neutrophils was investigated using a pharmacological approach. In vivo release of
MMP-9 and NE in mice exposed to cigarette smoke (CS) and/or the TLR agonist lipopolysaccharide (LPS) in the presence of
dexamethasone (Dex) was investigated.
Results: Neutrophil activation as assessed by NE release was increased in severe COPD (36-fold, GOLD II vs. IV). MMP-9 levels
(8-fold) and activity (21-fold) were also elevated in severe COPD, and this activity was strongly associated with BALF
neutrophils (r=0.92, p,0.001), but not macrophages (r=0.48, p=0.13). In vitro, release of NE and MMP-9 from fMLP
stimulated blood neutrophils was insensitive to Dex and attenuated by the PI3K inhibitor, wortmannin. In vivo, GC resistant
neutrophil activation (NE release) was only seen in mice exposed to CS and LPS. In addition, GC refractory MMP-9 expression
was only associated with neutrophil activation.
Conclusions: As neutrophils become activated with increasing COPD severity, they become an important source of NE and
MMP-9 activity, which secrete proteinases independently of TIMPs. Furthermore, as NE and MMP-9 release was resistant to
GC, targeting of the PI3K pathway may offer an alternative pathway to combating this proteinase imbalance in severe
COPD.
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Introduction
Proteinases generated within the lung environment regulate
many physiological processes during infection, inflammation and
subsequent tissue repair. Innate immune cells including macro-
phages and neutrophils are a major source of matrix metallopro-
teinase-9 (MMP-9) and neutrophil elastase (NE), which are central
to these processes. In the normal setting, anti-proteinases such as
a1-antitrypsin (a1-AT), secretory leukoprotease inhibitor (SLPI)
and tissue inhibitor of metalloproteinases (TIMPs) are in excess
and provide an anti-proteinase screen to prevent deleterious effects
[1]. In lung diseases such as chronic obstructive pulmonary disease
(COPD) there is an imbalance leading to excessive proteinase
activity that can cause host tissue damage [1]. Activated
neutrophils release serine proteinases including NE, Proteinase-3
(PR-3) and MMPs including MMP-9 and MMP-8, which have
been shown to be elevated in COPD (reviewed in [2]). COPD is
primarily caused by cigarette smoke exposure and is already the
fifth leading cause of death worldwide [3]. As the disease
progresses, increased susceptibility to respiratory virus and/or
bacteria promote acute exacerbations (AECOPD) that further
amplifies inflammation [4,5]. Glucocorticosteroids (GCs) are a
mainstay for current AECOPD management, although their
efficacy in COPD is suboptimal as neutrophilic inflammation
persists following GC treatment [6].
Elevated MMP-9 levels in COPD are related to sputum
neutrophil numbers to suggest that this cell type is a major source
[7,8]. Neutrophils contain tertiary gelatinase granules formed at
later stages of myelopoiesis that act as a major reservoir for the
rapid exocytosis of MMP-9 [9]. This can result in increased local
proteolytic activity because unlike other mononuclear leukocytes,
this cell type does not express the inhibitor, TIMP1 [10]. MMP-9
degrades collagen, elastin and gelatin and its levels inversely
correlate with airflow obstruction [7]. Extracellular matrix derived
N-acetyl Pro-Gly-Pro (Ac-PGP) also augments MMP-9 release
from neutrophils [11]. NE is abundant in primary azurophil
granules formed during the early stages of myelopoiesis and is
secreted during neutrophil degranulation [9]. Free NE activity
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release their intracellular content. NE activity is elevated in COPD
and the degree of NE localised to lung elastic fibers correlates with
the degree of emphysema [12]. NE can degrade extracellular
matrix components including elastin, collagens I-IV and fibrino-
gen and the genetic deficiency in a1-AT is associated with early
onset pan lobular emphysema [13]. Serine proteinases such as NE
are considered to be at the apex of the proteinase hierarchy in
airways as they have the ability to activate MMPs including MMP-
9 via cleavage of pro-MMP-9 into active-MMP-9 [14]. Further-
more, NE preferentially degrades TIMP1 that is bound to MMP-
9, thereby liberating active MMP-9 [15]. NE can also activate the
inflammatory NFkB pathway via a Toll-Like Receptor-4 (TLR-4)
dependent manner and promote an acute inflammatory response
[16]. The promoter of MMP-9 also contains an NFkB binding site
that promotes its expression [17].
Here, we have directly measured secreted MMP-9 and NE in
BAL–fluid (BALF) from a COPD cohort stratified according to
GOLD stages and have shown that NE and MMP-9 activity
increase with disease severity. In addition, neutrophils were strongly
related to both proteinases in severe COPD. We hypothesised that
neutrophils are an important source of NE and MMP-9 that is
insensitive to GCs. To examine this, we have assessed their release
from isolated blood neutrophils in the presence of pharmacological
inhibitors and in an in vivo inflammatory model that combines CS
exposure and acute inflammation (LPS).
Results
Airway neutrophils release MMP-9 and NE in COPD
COPD severity was classified as moderate (stage II, n=9 (31%)),
severe(stageIII,n=9(31%)),andverysevere(stageIV,n=11(38%))
according to GOLD criteria as previously described [18]. Inhaled
corticosteroid (ICS) daily usage increased across the severity grades as
summarised in Table 1. Neutrophil BALF numbers increased with
disease severity (GOLD II; mean 0.18 (range 0.04–0.45), GOLD III;
1.12 (0.03–8.5) and GOLD IV; 1.83 (0.05–13.4) neutrophils (610
6
per mL) with a significant increase observed in GOLD IV vs. GOLD
II (p,0.05, Figure 1A). NE activity also increased with disease
severity (GOLD II; mean 0.016 (range 0.007–0.04), GOLD III; 0.25
(0.002–1.25) and GOLD IV; 0.57 (.007–1.31) with a significant
increase observed in GOLD IV vs. GOLD II (p,0.05,F i g u r e1 B ) .
There was a positive correlation between neutrophil BALF numbers
and NE activity (Figure 1C; r=0.65, p,0.001).
Increased MMP-9 is associated with increased
neutrophilic inflammation in severe COPD
Gelatin zymography of COPD BALF identified major bands of
activity within the 90 kDa range, which is consistent with the
molecular weight of pro (92 kDa) and active (82 kDa) MMP-9
(Figure 2A). Total MMP-9 (pro and active forms) in BALF was next
measured by quantitative ELISA. The expression of MMP-9
increased with COPD severity (GOLD II; mean 137 (range 17.7–
301), GOLD III; 833 (50–5360) and GOLD IV; 1127 (88.6–8820)
ng/mL with a significantincrease observedinGOLDIVvs.GOLD
II (p,0.05, Figure 2B). Active MMP-9 quantified using flourescein
conjugated gelatin as a substrate also showed an increase in MMP-9
activity with COPD severity (GOLD II; mean 0.43 (range 0.21–
0.81), GOLD III; 4.78 (0.21–30.4) and GOLD IV; 8.96 (0.17–
27.4)610
4 RFU, with a significant increase observed in GOLD IV
vs. GOLD II (p,0.05, Figure 2C). There was a strong correlation
between MMP-9 expression and gelatinase activity, confirming
MMP-9 as the major gelatinase enzyme in severe COPD BALF
(Figure 2D; r=00.86, p,0.001). There was also a strong association
between BALF neutrophils and MMP-9 expression (Figure 3A,
r=0.89, p,0.001) and activity (Figure 3B, r=0.92, p,0.001)i n
GOLD IV COPD. BALF macrophages and MMP-9 expression
(Figure 3C, r=0.38, p=0.25) and activity (Figure 3D, r=0.48,
p=0.13) were not significantly associated in severe COPD.
Stimulated blood neutrophils rapidly release MMP-9 and
NE in a GC refractory manner
Isolated blood neutrophils stimulated with fMLP rapidly release
(20 min) NE (Figure 4A) and MMP-9 (Figure 4B) in a Dex
resistant manner. Pretreatment for 15 min prior to fMLP
stimulation with the PI3K inhibitor, wortmannin, blocked release
of NE and MMP-9 by ,50% (Figure 4C & D), whereas the
MAPK inhibitors (U0126; Erk pathway and SB203580; p38
pathway) were only effective in reducing MMP-9 release by 22%
and 42% respectively (Figures 4C & D).
CS promotes GC resistant airway inflammation
Intraperitoneal administration of Dex (20 mg per day) over four
days induced involution ofthe thymus, a positive control observation
for in vivo steroid activity, resulting in a 58% decrease in thymus
weight when compared with saline-treated mice (Figure 5A). CS
and/or LPS did not significantly alter thymus weight and Dex-
induced thymic involution was not altered by either stimulus. Sub-
chronic CS exposure caused a significant increase in total BALF cell
numbers (vehicle; 160.19 vs. CS; 3.660.18610
5 cells, p,0.05)t h a t
was completely refractory to Dex treatment (Figure 5B). LPS
challenge increased total BALF numbers (10.261.1610
5 cells) in a
manner that was reduced by Dex (49%). CS exposure prior to LPS
reduced the efficacy of Dex, where only a 21% reduction in total cell
numbers was observed. BALF macrophages were only increased in
CS exposed mice (,2-fold) that was not significantly altered by LPS
or Dex treatment (Figure 5C).
Neutrophil activation is associated with GC refractory
MMP-9 release in vivo
CS exposure increased BAL neutrophil numbers (vehicle;
0.0860.04 vs. CS; 1.960.21610
5, p,0.05) in a Dex insensitive
Table 1. COPD patient characteristics.
GOLD Criteria n M:F Age (range) Pack Years (range) % using ICS
#Total daily ICS dose (range)
II 9 5:4 64 (56–72) 40 (20–70) 3/9 (33%) 311 (0–1000)
III 9 6:3 70 (60–75) 35 (20–150) 5/9 (56%) 566 (0–1000)
IV 11 7:4 74 (69–80) 45 (20–116) 10/11 (91%) 1070 (0–1600)
#Total daily ICS dose (beclamethasone equivalents), based on the assumption that 1 mg.
beclomethasone=1 mg Budesonide=0.5 mg Fluticasone.
doi:10.1371/journal.pone.0033277.t001
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numbers (9.02261.1610
5 neutrophils/mL) and Dex suppressed
this response by 54%. The combination of LPS and CS did not
significantly alter the LPS neutrophilic response but did reduce the
efficacy of Dex to 23%. NE activity in BALF was not significantly
altered by CS, Dex or LPS treatment (Figure 6B). The
combination of CS and LPS significantly increased NE activity
(vehicle; 100615.6 vs. CS-LPS; 176615.6%, p,0.05). The
response was further increased in the presence of Dex
(222617.7%). MMP-9 expression in BALF was modestly
increased in CS exposed mice and insensitive to Dex (Figure 6C).
There was a large increase in MMP-9 expression in LPS-
challenged mice (vehicle; 30.9610.7 vs. LPS; 3357164930,
p,0.05) and Dex suppressed this response by 89%. CS exposure
prior to LPS reduced the efficacy of Dex, where a 42% reduction
in MMP-9 was observed.
Discussion
The close association between MMP-9 and BALF neutrophils in
our COPD cohort identify this cell type as a major source of
MMP-9. Increasing MMP-9 and NE with disease severity in the
presence of increasing ICS dosage is consistent with enhanced
neutrophil activation and degranulation. Our in vitro data
demonstrates that fMLP stimulated blood neutrophils release
granules containing MMP-9 and NE in a GC resistant manner.
Furthermore, degranulation of NE and MMP-9 share similar
signalling pathways (PI3K dependence), but diverge in their
requirement for MAPK signalling, where only MMP-9 was
reduced by Erk and p38 pathway inhibition. Our findings are
consistent with previous observations that also identified MAPK
(Erk1/2 and p38) [19] signalling as necessary for MMP-9
degranulation. The release of MMP-9 by neutrophils can also
occur in response to other inflammatory mediators such as
CXCL8 [20], TNFa [21] and endotoxin [22]. Unlike denovo
MMP-9 production by other cell types such as macrophages, this
response occurs rapidly and is released independently of TIMP1,
as neutrophils do not produce this anti-proteinase [10]. MMP-9 is
formed in the later stages of neutrophil maturation and this
proteinase contributes to neutrophil extravasation and stem cell
mobilisation [23,24] via the degradation of basement membrane
collagens, whereas NE is primarily responsible for pathogen killing
(reviewed in [25]).
Primary azurophilic granules containing NE normally undergo
limited exocytosis and are traditionally associated with the
intracellular killing of microorganisms in the phagolysosome, as
mice deficient in NE are more susceptible to gram negative
bacteria [26]. The majority of NE is expressed on the neutrophil
surface during activation, with less than 5% being released into the
extracellular milieu [27]. In COPD, free NE activity may be
further increased by necrotic neutrophils. Haemophilus Influenzae is a
common gram negative pathogen in COPD that chronically
colonises the airways and directly causes neutrophil necrosis and
release of azurophilic granular content [28]. In vivo, only CS-
primed neutrophils release free NE activity in response to LPS
challenge in a manner that was completely refractory to GCs. The
hierarchy of granular release is only partially understood and
involves intracellular calcium changes that can differentially
regulate degranulation, where azurophilic granule release is
dependent on calcium transient, in contrast to CXCL8-mediated
gelatinase exocytosis [29]. Calcium changes regulate soluble-N-
ethylmaleimidesensitive-factor accessory-protein receptors
(SNAREs), a system responsible for fusion of granules with the
plasma membrane [30] and the density of SNAREs may regulate
exocytosis potential. Components of CS such as nicotine have
been shown to increase intracellular calcium levels in neutrophils
[31], however it is not known whether this response further primes
azurophilic exocytosis or whether the expression or function of
SNAREs are altered with increasing COPD severity.
In vivo, MMP-9release was maximalinresponsetoLPSchallenge
in a manner that was effectively blocked by GCs. This occurred in
Figure 1. Neutrophilic airway inflammation increases with
disease severity. (A) BALF neutrophils were higher in very severe
COPD (GOLD IV) compared to participants with moderate COPD (GOLD
II). (B) NE activity stratified across the GOLD stages demonstrates
increased NE activity in GOLD IV. (C) Neutrophils were positively related
to NE activity (Spearman r=0.65, p,0.001) in BALF. Individual data
points are shown with line representing mean values. # p,0.05 versus
GOLD II.
doi:10.1371/journal.pone.0033277.g001
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concurrent NE release. The absence of neutrophil activation
suggests that alternative cellular sources are producing MMP-9 in
response to LPS alone, such as alveolar macrophages. Alveolar
macrophages increase production of MMP-9 in response to LPS
stimulation in a GC sensitive manner [32], which is consistent with
our in vivo data. In COPD, epigenetic deregulation in COPD
macrophages is associated with oxidant dependant loss of HDAC2
expression and subsequent loss of GC mediated suppression of
inflammatory genes [33]. In addition, our data support neutrophil
activation of as an alternative mechanism for GC refractoryMMP-9
release. We found that CS priming and LPS challenge promoted
neutrophil activationandthis wasassociated witha reductioninGC
efficacy to block MMP-9 in vivo. This data suggests that there is a
transition from macrophage to neutrophil mediated release of
MMP-9 in the presence of GCs and is consistent with our in vitro
findings where neutrophil derived MMP-9 was completely resistant
to GCs. Reduced Dex actions may also initiate a positive feedback
inflammatory loop, as matrix breakdown products further augment
neutrophil release of MMP-9 [11].
Elevated NE levels may also directly contribute to ongoing
inflammation. NE activates TLR-4 signalling to promote CXCL8
expression in bronchial epithelial cells via activation of NFkB
[16,34]. Whether NE directly engages TLR-4 or modifies a
required surface co-receptor or adaptor molecule has yet to be
elucidated. In addition, NE was identified at the apex of a signalling
cascade that can promote CXCL8 release via EGFR signalling in
bronchial epithelial cells [35]. This process involves the surface
shedding of EGFR ligands that initiate receptor transactivation and
subsequent activation of p38 and NFkB. EGFR transactivation is
also implicated in other pathological processes in COPD. NE
mediated activation of this pathway promotes airway mucin
production [36]. Furthermore, we have previously shown that
EGFR transactivation augments inflammatory responses initiated
by rhinovirus infection of bronchial epithelial cells [37].
In summary, we found that both NE and MMP-9 activity was
elevated in severe COPD and was closely related to neutrophilic
inflammation. In vivo, neutrophil activation was associated with GC
refractory release of MMP-9. In vitro, neutrophils rapidly release both
proteinases in a GC resistant manner that was dependent on PI3K
Figure 2. MMP-9 expression and activity increased in severe COPD. (A) Gelatin zymography (representative bands from each GOLD stage)
identify major bands of activity correlating to the molecular weight of pro (92 kDa) and active (82 kDa) MMP-9. (B) MMP-9 expression and (C) activity
increased with disease severity. (D) MMP-9 expression and gelatinase activity in GOLD IV BALF were strongly related (Spearman r=0.86, p,0.001).
Individual data points are shown with line representing mean values. # p,0.05 versus GOLD II.
doi:10.1371/journal.pone.0033277.g002
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dependent on Erk and p38 signalling. Neutrophil activation may
represent a fundamental mechanism of GC resistance in COPD, as
NEisatthe apexofinflammatory and mucuspathwaysanditsrelease
is completely resistant to GCs. By identifying the mechanisms for
neutrophil derived NE and MMP-9 release in chronic inflammatory
conditions and their lack of regulation by currently used anti-
inflammatoryagents such asGCs,bettertherapeuticstrategiescan be
designed to combat deregulated inflammation in COPD.
Methods
Ethics Statement
This research was approved by the Hunter New England
Human Research Ethics Committee of the Hunter New England
Area Health Service (HNEAH). All participants gave informed
written consent prior to their inclusion in this study. The animal
experiments were approved by the Animal Ethics Committee
(AEC) of the University of Melbourne and conducted in
compliance with the National Health and Medical Research
Council (NHMRC) of Australia.
Subjects
Fiberoptic bronchoscopy was performed on subjects with stable
COPD (n=29; GOLD II (n=9), GOLD III (n=9) and GOLD IV
(n=11). Patient characteristics are summarized in Table 1. The
percentage use and daily dosage of ICS at time of sampling is
summarized in Table 1. Warmed saline (2660 mL) was instilled
into the airways to enable recovery of BAL cells and BAL fluid
(BALF). BAL cells were collected by centrifugation (4006 g for
5 min) and cytospot slides were prepared and stained for
differential cell analysis based on morphology. Cell free BALF
was archived at 280uC for future analysis.
Proteinase Assays
Measurement of NE activity in BALF and supernatant was
determined using the specific NE substrate methoxysuccinyl-
alanyl-alanyl-prolyn-valylpapnitroanalide (MEOSAAPVNA, Sig-
ma; St Louis, MO). Neat BALF (5 mL) was diluted to 200 mLN E
Buffer containing final concentrations of 0.2 mM MEO-
SAAPVNA, 50 mM Tris-HCl (pH 7.5), 5 mM CaCl2,1 m M
ZnCl2 and 0.01% sodium azide. Absorbance at 405 nm was
measured using microplate reader (MultiScan Ascent, Thermo).
Zymography was used to quantify gelatinase activity in BALF,
which identified major gelatinase bands observed at ,90 kDa
corresponding to MMP-9 as previously published [38]. Briefly,
gelatin substrate (2 mg/mL, LabChem Inc, Pittsburgh, PA) was
incorporated into SDS polyacrylamide mini-gels (10%) before
casting. BALF (10 mL) was run into gels at a constant voltage
(200 V) under non-reducing conditions. Gels were washed twice in
Figure 3. MMP-9 is associated with neutrophilic inflammation in COPD. (A) MMP-9 expression was positively associated with BALF
neutrophils in GOLD IV COPD (Spearman r=0.0.89, p,0.001). (B) MMP-9 activity was also positively associated with BALF neutrophils in GOLD IV
COPD (Spearman r=0.0.92, p,0.001), whereas no association was observed with BALF macrophages (C & D).
doi:10.1371/journal.pone.0033277.g003
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overnight at 37uC in zymography buffer (50 mM Tris-HCl
(pH 7.5), 5 mM CaCl2, 1 mM ZnCl2 and 0.01% sodium azide).
The gels were then stained with Coomassie Brilliant Blue R-250
(Sigma St Louis, MO) for 45 minutes and extensively destained.
After destaining, zones of enzyme activity appeared clear against
the background of Coomassie Blue stain.
Total MMP-9 levels (pro and active forms) were assessed using
quantitative ELISA (DuoSet ELISA, RnD Systems) in accordance
with the manufacturer’s instructions. Measurement of MMP-9
activity in BALF and was determined using fluorescein labeled
DQ gelatin substrate (Life Technologies), which is only cleaved by
the active form of the enzyme. Neat BALF (40 mL) was diluted to
200 mL Buffer containing final concentrations of 3 mg fluorescein
labeled DQ gelatin substrate, 50 mM Tris-HCl (pH 7.5), 5 mM
CaCl2, 1 mM ZnCl2 and 0.01% sodium azide. Fluorescence
intensity (relative fluorescence units, RFU) was measured using a
fluoresecence microplate reader with standard fluorescein filters.
Digested products from DQ Gelatin have absorption maxima of
495 nm and emission maxima of 515 nm.
In vitro Analysis
All reagents were obtained from Sigma-Aldrich unless otherwise
stated. Venous blood was collected upon receipt of written consent
from healthy volunteers. Neutrophils were isolated by Ficoll-Paque
density gradient centrifugation. The pellet enriched for erythro-
cytes and neutrophils was next mixed with an equal volume of 6%
Dextran T500 in saline and allowed to sediment for 20 min. The
neutrophil enriched upper layer was removed and contaminating
erythrocytes were removed by hypotonic lysis. Cell viability was
checked using Trypan blue exclusion method and was routinely
found to be.95%. Neutrophil purity was confirmed by differential
staining to be .95%. Neutrophils were resuspended to 2610
6 cells
per mL in Krebs Buffer and incubated with 5 mg/mL Cytocha-
lasin B for 15 min prior to stimulation. Isolated cells were also
pretreated with Dex (100 nM), wortmannin (100 nM), U0126
(1 mM) or SB203580 (1 mM) at 37C for 15 min prior to fMLP
stimulation (100 nM, 37C for 20 min). At the end of the
incubation, cell free supernatant was retained by centrifugation
at 1000 g for 5 min and archived at 280C prior to NE and MMP-
9 analysis.
Figure 4. Neutrophils release NE and MMP-9 in a GC resistant manner. Isolated blood neutrophils from healthy volunteers were pretreated
with Vehicle (Veh, 0.01% DMSO) or Dex (100 nM) for 15 min prior to fMLP stimulation (100 nM, 20 min at 37C) and (A) NE activity and (B) MMP-9
release was determined. Isolated neutrophils were also pretreated with wortmannin (Wort, 100 nM), U0126 (U0, 1 mM) and SB203580 (SB, 1 mM) prior
to fMLP stimulation and cell free supernatants were retained for assessment of (C) NE activity and (D) MMP-9 expression as a percentage of the fMLP
positive control. Data is presented as the mean6SEM of the 3 replicates from an individual donor and is representative of 3 separate experiments.
doi:10.1371/journal.pone.0033277.g004
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Specific pathogen-free male Balb/c mice aged 7 weeks and
weighing ,20 g were obtained from the Animal Resource Centre
Pty. Ltd. (Perth, Australia). The animals were housed at 20uCo na
12-h day/night cycle in sterile micro-isolators and fed a standard
sterile diet. Mice were treated with Dex (1 mg/kg, i.p.) for 2 hours
prior to CS exposure. For the sub-chronic CS exposure protocols,
mice were placed in an 18 liter perspex chamber in a class II
biosafety cabinet as previously described [39] with some minor
Figure 5. CS exposure reduces the efficacy of Dex to suppress
acute airway inflammation. Mice were treated with Saline (open
bar) or Dex (closed bar, 1 mg/kg i.p) once daily over 4 days for 2 hours
prior to CS exposure as detailed in methods. On Day 4, mice were
treated intranasally with saline (VEH) or LPS (1 mg). Following 24 hour
LPS challenge mice were sacrificed and (A) thymus weight was
recorded. BAL was also performed and (B) total cell and (C)
macrophages numbers were determined by differential cell counting
analysis. d Two-way ANOVA (Sal versus Dex, p,0.05). # One-way
ANOVA (versus VEH, p,0.05).
doi:10.1371/journal.pone.0033277.g005
Figure 6. Differential MMP-9 and NE activity and altered GS
responses in vivo. (A) BALF neutrophil numbers were determined
from treatment groups as detailed in Figure 5 legend. BALF was
retained and (B) NE activity and (C) MMP-9 expression (Insert:
representative zymography results) was determined as detailed in
methods (C) d Two-way ANOVA (Sal versus Dex, p,0.05). # One-way
ANOVA (versus VEH, p,0.05). The data was pooled from 2 separate
experiments (n=5–10 mice per treatment group).
doi:10.1371/journal.pone.0033277.g006
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sidestream CS generated from one cigarette (2R4F, University of
Kentucky, Lexington, KY) for 15 min and allowed to recover for
2 hours.The levels of carboxyhemoglobin in the blood of Balb/c
mice exposed to CS using this model have previously been
measured and found to be comparable to that observed in smokers
[39]. This process was repeated 2 times for a total of 3 cigarettes
per day over four days. On the fourth day, the final CS exposure
was replaced by treating the mice with LPS. For LPS challenge,
mice were anesthetised by methoxyflurane (Medical Developments
International Ltd, Springvale, Australia) inhalation and treated
intranasally with 1 mg LPS diluted in 50 mL PBS. Saline was used
as a control for Dex and LPS. Following 24 hours, thymus weight
was also recorded as a quantitative measure of GC activity. BAL
was also performed via tracheotomy (SP30 Duran polyethylene
tubing) proximal to the larynx and total/differential BAL cell
counts were performed as previously described [40]. Cell free
BALF was archived at 280uC prior to analysis of MMP-9 and NE
activity.
Statistical analysis
Normally distributed data were expressed as mean 6S.E. For
the clinical samples Mann Whitney U test was used to analyze the
data. Spearman correlation was used to assess the relationship
between secreted proteinases and neutrophil numbers in BALF
and the relationship between MMP-9 and NE. For the animal
studies, significance between groups was tested using either one-
way or two-way analysis of variance (ANOVA) followed by
Dunnetts comparison test where p#0.05 was considered signifi-
cant.
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